Physician practice in the management of congestive heart failure  by Hlatky, Mark A. et al.
966 JACCVol. 8, No.4
October 1986:966-70
Physician Practice in the Management of Congestive Heart Failure
MARK A. HLATKY, MD, FACC,* JEROME L. FLEG, MD, FACC,t PATRICIA C. HINTON, MS, II
EDWARD G. LAKATTA, MD,t FRANK 1. MARCUS, MD, FACC,t
THOMAS W. SMITH, MD, FACC,§ HAROLD C. STRAUSS, MD*
Durham, North Carolina; Baltimore, Maryland; Tucson, Arizona; Boston, Massachusetts; and Dallas, Texas
The syndrome of congestive heart failure may complicate
virtually any form of cardiac disease. In the United States,
an estimated 400,000 individuals develop heart failure an-
nually, and roughly 2,300,000 individuals had heart failure
in 1983 (1). Congestive heart failure is the primary reason
for approximately 497,000 hospital admissions and 4,825,000
hospital days annually (2), as well as numerous physician
visits and considerable prescription drug use. The prognosis
of heart failure remains dismal, with less than 50% of pa-
tients surviving 5 years (1,3,4).
New insights into the pathophysiology of congestive heart
failure have been achieved in the past decade and swiftly
translated into novel therapeutic approaches. Vasodilating
drugs have been added to digitalis and diuretic agents as
therapeutic options, and newer inotropic agents are undergo-
ing clinical investigation. The feasibility of discontinuing
digitalis in selected patients with heart failure has been ex-
plored (5,6). The impact of these developments on medical
practice is unknown, however. We undertook a survey of
physicians to determine how recent changes in the under-
standing and treatment of heart failure had been accepted
into practice. In this report we summarize some of the major
findings of this survey and discuss their implications.
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The survey was conducted under the auspices of the
American Heart Association. A four page self-administered
questionnaire containing 75 items was designed (available
on request). Survey participants were drawn from two sources.
First, a stratified random sample of about 1,500 physicians
in each of three practice settings (cardiology, internal med-
icine, family/general practice) was drawn from the Amer-
ican Medical Association's Physician Masterfile. In addi-
tion, all 1,306 cardiologists on the staffs of Americanmedical
schools listed by the Association of American Medical Col-
leges were also asked to participate. Survey questionnaires
were mailed to 5,830 physicians at the end of March 1984.
A total of 2,704 usable responses was received, an overall
46% response rate. Characteristics of respondents are listed
in Table 1.
Clinical Diagnosis of Congestive
Heart Failure
A clinical diagnosis of congestive heart failure may com-
mit a patient to a lifetime of drug therapy. We consequently
explored the diagnostic value of physical findings consid-
ered in the differential diagnosis of dyspnea (Fig. 1). There
was a clear consensus that an S3gallop was the most specific
single sign of congestive heart failure. Other individual signs
were, by themselves, considered only suggestive of heart
failure, but combinations of signs were considered strong
evidence of heart failure. We did not investigate which
laboratory tests, if any, were considered necessary to es-
tablish a diagnosis of heart failure or investigate its etiology.
One of the most remarkable findings of our survey was
the wide spectrum offindings considered diagnostic ofheart
failure, even by academic cardiologists. This finding sug-
gests that many patients may be treated inappropriately for
a diagnosis of heart failure based on nonspecific signs and
symptoms. There is, however, no universally accepted def-
inition of heart failure. Although several operational defi-
nitions for congestive heart failure have been proposed (4,7),
there is little evidence that any has been accepted by either
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Table 1. Characteristics of Survey Participants
researchers or clinicians. Indeed, most randomized trials of
drug therapy for congestive heart failure have not defined
the criteria used for diagnosis. Further work to develop and
disseminate validated clinical criteria for this diagnosis is
long overdue.
Initial Drug Treatment of Congestive
Heart Failure
Patterns of drug prescription for congestive heart failure
were explored in the survey with several questions. Partic-
ipants were asked, "What is the best initial drug therapy
for an outpatient in sinus rhythm with chronic congestive
heart failure?" Fifty-three percent of respondents would
give diuretic drugs alone, 7% would give digitalis alone and
30% would give the combination of digitalis and diuretic
agents. Vasodilating agents, either alone or in combination,
were the choice of 9% as the best initial treatment of chronic
heart failure.
These findings clearly demonstrate that physicians re-
gard diuretic drugs as first line therapy for congestive heart
failure. Further analysis of the pattern of responses suggests
that drug therapy was used mainly to relieve symptoms
rather than to affect the underlying pathophysiology or prog-
nosis. Digitalis was more likely to be included in the initial
regimen if, in order of importance, the physician 1) believed
that the drug improved exercise tolerance, 2) did not regard
once recommended for most patients with heart disease,
including patients with congestive heart failure. The past
two decades have brought early ambulation and early hos-
pital discharge after myocardial infarction and the wide-
spread use of exercise conditioning for patients with heart
disease. Exercise conditioning has been shown to decrease
symptoms in selected patients with left ventricular dys-
function (8), but systematic evaluation of its effects in pa-
tients with frank congestive heart failure has not been per-
formed. The survey suggests the need for further evaluation
of the optimal activity prescription for such patients.
A wide spectrum of opinion was also evident about the
relative roles ofdietary sodium restriction and diuretic ther-
apy in manipulating sodium balance in patients with conges-
tive heart failure. For class II patients, dietary sodium was
not restricted at all by 1% of respondents, avoidance of salty
foods was recommended by 5%, no added salt at the table
by 35%, no added salt in cooking or at the table by 35%
and a 2 g or less sodium diet by 24%. For class III patients,
however, 68% advised a 2 g or less sodium diet. These
findings suggest that physicians often use diuretic drugs to
allow a more liberalized diet for patients with mild failure.
Presumably, a liberalized diet permits better nutrition, but
empirical support for this supposition is lacking and more
intensive diuretic therapy depletes potassium stores. A vast
majority (75%) of physicians who prescribe diuretic agents
also prescribe potassium supplements, and virtually all (95%)
who prescribe both digitalis and diuretic drugs also prescribe
potassium supplements. The relative effects of diuretic agents
and dietary restriction on sodium and potassium balance and
nutrition need clarification.
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Figure 1. Percentof respondents whoconsidered various physical
signs as eitherdiagnostic (black area) or strongly suggestive (white
area) of congestive heart failure. Edema = pedal edema; i JVP
= increased jugular venous pressure; Rales =' basilar rales.
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General Measures for Congestive
Heart Failure
A variety of ancillary measures are often prescribed for
patients with congestive heart failure. Survey respondents
outlined their activity and diet recommendations for patients
with New York Heart Association class II congestive heart
failure. Only 19% restrict physical activity, whereas 31%
recommend normal physical activity, 38% recommend light
regular exercise and 12% recommend an exercise condi-
tioning program. This diversity of responses with regard to
activity was an unexpected finding of the survey. Rest was
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Table 2. Physician Opinions About Efficacy of Digitalis or Vasodilators for Various End Points
Agree (%) Disagree (%) No Opinion (%)
Drug Effect Dig Vaso Dig Vaso Dig Vaso
Improves exercise tolerance 67 90 25 5 7 5
Prolongs life in CHF due to:
AR or MR 39 35 46 38 15 27
Coronary disease 26 34 57 42 16 24
Cardiomyopathy 36 33 48 42 16 25
Prevents CHF due to:
Noncardiac surgery 19 77 4
AR orMR 41 33 54 56 5 II
Cardiomyopathy 41 30 54 58 5 12
Totals may not equal 100% because ofrounding ofvalues. AR = aortic regurgitation; CHF = congestive
heart failure; Dig = digitalis; MR = mitral regurgitation; Vaso = vasodilator.
digitalis. Physicians who agreed that the risk of digitalis
toxicity is increased in these clinical settings were less likely
to use digitalis as the initial treatment of heart failure and
more prone to discontinue the drug in patients with mild
heart failure.
Figure2. Percent of respondents who either strongly agreed (black
area) or agreed (white area) that digitalis should be discontinued
in clinically stable patients in normal sinus rhythm andtaking low
doses of diuretic agents, in various clinical settings. CHF =
congestive heart failure; EF = ejection fraction; SUB-TX = sub-
therapeutic .
Vasodilators and Congestive Heart Failure
Vasodilators represent a new approach to the treatment
of congestive heart failure. There was a consensus that they
improve exercise tolerance in patients with congestive heart
failure (Table 2), and that their use can be initiated in the
ambulatory setting without prior pulmonary artery cathe-
terization. The most commonly used vasodilators were, in
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digitalis as toxic in common clinical situations, and 3) be-
lieved that digitalis therapy improved prognosis. In contrast,
belief that vasodilators decrease symptoms and improve ex-
ercise tolerance had no independent effect on their inclusion
in the initial drug regimen. Our findings suggest that prac-
ticing physicians will require strong evidence that vasodi-
lators or inotropic agents improve prognosis before these
agents will be considered as first line therapy for congestive
heart failure.
Digitalis and Congestive Heart Failure
Considerable controversy surrounds the use of digitalis
to treat chronic congestive heart failure and the pattern of
responses in this survey confirms a wide spectrumof opinion
on use of the drug. Although digitalis was considered ef-
fective in improving exercise tolerance by 67% of respon-
dents (Table 2), only 7% would initiate therapy for heart
failure with digitalis alone. There was also a clear tendency
to discontinue digitalis treatment in patients with mild symp-
toms (Fig. 2), particularly if the diagnosis of heart failure
had been poorly documented or if heart size and ejection
fraction were normal. Only about half of the physicians
agreed with recent suggestions that digitalis can be safely
discontinued in patients with subtherapeutic digoxin levels
(9) or without an S3 gallop (10). Nevertheless, virtually all
physicians treated patients with moderately severe conges-
tive heart failure with digitalis.
The tendency to reserve digitalis for more severely af-
fected patients with heart failure may stemfrom a perception
of the drug as potentially toxic. We chose to examine four
common clinical settings in which some evidence suggests
that the risk of digitalis toxicity is increased: old age (11),
lung disease (12), postmyocardial infarction (13,14) and
preexisting ventricular arrhythmia. A consensus existed that
digitalis was more toxic in the elderly than in younger pa-
tients (Fig. 3). Opinion was sharply divided, however, about
the other three groups reported to be at increased risk from
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Figure 3. Percent of respondents who either strongly agreed (black
area) or agreed (white area) that the risk of toxicity or death is
increased when digitalis is used for congestive heart failure in
patients in various clinical settings . COPD = chronic obstructive
pulmonary disease ; Post MI = first year after myocardial infarc-
tion; PVCs = preexisting premature ventricular complexes.
order of preference , nitrates, captopril , hydralazine and pra-
zosin. Very few respondents used a vasodilator as part of
the initial drug regimen for congestive heart failure . Fur-
thermore, respondents indicated that only half of their pa-
tients with class III heart failure were taking a vasodilator.
The reason for this apparent discrepancy betwee n the nearly
universal belief in the efficacy of vasodilators and their
relatively infrequent use in practice remains specu lative. It
may be related, in part , to the prevalent belief that the
effec tiveness of many of these agents is gradually lost over
time (Table 3), or perhaps to lack of familiarity with this
new class of drugs.
Effect of Therapy on Natural History of
Congestive Heart Failure
The survey revea led a clear conse nsus that drug therapy
of congestive heart failure is effec tive in relieving symptoms
and improving exercise tolerance. There was very little be-
lief, however, that medical therapy actually improves sur-
vival. As shown in Table 2, only 26 to 39% of respondents
agreed that either digitalis or a vasodilator improves survival
in congestive heart failure arising from a variety of causes.
As discussed by Furberg and Yusuf (15) , most previous
randomized trials of therapy in conges tive heart failure have
enrolled too few patients to confidently establish an effec t
on patien t survival. These findings support the need for a
large randomized study to establish the effect of therapy on
survival.
Intervention earlier in the course of congestive heart
failure would be indicated if a drug were shown to alter the
natural history of this disease . We found that physicians
who strongly believe that digitalis therapy prolongs life were
more likely to prescribe digitalis to patients with asymp -
tomatic left ventricular dysfunc tion and to use digitalis as
initial therapy for symptomatic congestive heart failure.
Similar findings were evident with regard to vasodi lators.
These findings suggest that physicians are likely to respond
to any demonstration that treatment alters the prognosis of
severe congestive heart failure by applying this treatment
to patients with milder forms of the disease , and even to
patients with asymptomatic left ventricular dysfunction. It
will be important to verify directly the effect of therapy on
outcome across the spectrum of severity in congestive heart
failure .
Conclusions
The documentation in this survey of sharply divided opin-
ion or lack of opinion, or both , in severa l import ant areas
suggests the need for further clinical research concerning
congestive heart failure . Although most respondents viewed
both digitalis and vasodil ating drugs as effective in relieving
the symptoms of heart failure, few would prescribe these
drugs to prevent the development of heart failure in asymp-
tomatic patients at high risk. A considerable frequency of
"no opinion" responses (16 to 27%) was recorded con-
cerning whether drug treatment actually prolongs survival
in patients with congestive heart failure . These findings
Table 3. Physician Opinions Regarding Specific Vasodilators
Choice (%) Tolerance Develops (%)
First* Second Agree Disagree No Opinio n
Nitrates 39 16 35 50 15
Captopril 21 20 17 48 35
Hydralazine 16 20 42 40 18
Hydra lazine and nitrate 16 17 NA NA NA
Prazosi n 9 15 63 12 24
Nifedipine 4 9 13 37 50
*Totals are greater than 100% because some respondents listed more than one first choice . NA 0= not
available .
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suggest that a randomized clinical trial to test whether early
treatment of preclinical left ventricular dysfunction prevents
the development of heart failure, and whether drug treatment
prolongs life in patients with established congestive heart
failure, is particularly timely and will fill a large gap in
knowledge (15). Some other investigations suggested by the
results of this survey include those to develop validated
clinical criteria for heart failure diagnosis, to determine the
role of exercise training and activity restriction in heart
failure and to determine the best initial drug treatment of
congestive heart failure.
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